Welcome to Shanghai Probechem Biochemicals Co Ltd !Global Supplier of Chemical Probes, Inhibitors & Agonists.
Chemical Structure : E-CFCP
Catalog No.: PC-49649Not For Human Use, Lab Use Only.
E-CFCP is a novel long-acting nucleotide reverse transcriptase inhibitor (NRTI) against HBV, shows potent activity against HBV WTD1 and HBV WTC2 with IC50 of 1.8 and 0.7 nM, respectively.
Bulk size, bulk discount!
E-mail: sales@probechem.com
Tech Support: tech@probechem.com
E-CFCP is a novel long-acting nucleotide reverse transcriptase inhibitor (NRTI) against HBV, shows potent activity against HBV WTD1 and HBV WTC2 with IC50 of 1.8 and 0.7 nM, respectively.
E-CFCP exhibited potent anti-HBV activity in HBV-exposed PXB-cells, blocked the production of intracellular HBV-DNA by IC50qPCR_cell with IC50 of 0.01 nM.
E-CFCP exerted potent activity against ETV-resistant and ADV-resistant HBV variants, HBVETV-RL180M/S202G/M204V (IC50SB_cell=57.2 nM), also potent against HBVADV-RA181T/N236T (IC50SB_cell=6.2 nM).
E-CFCP does not shows significant mtDNA synthesis inhibition in PBMCs and PXB-cells.
Once-daily peroral E-CFCP administration over 2 weeks (0.02∼0.2 mg/kg/day) reduced HBVWTC2-viremia by 2–3 logs in PXB-mice without significant toxicities and the reduction persisted over 1–3 weeks following treatment cessation.
| M.Wt | 320.28 | |
| Formula | C13H13FN6O3 | |
| Appearance | Solid | |
| Storage |
|
|
| Solubility |
10 mM in DMSO |
|
1. Higashi-Kuwata N, et al. J Hepatol. 2021 May;74(5):1075-1086.
Copyright © 2022 probechem.com. All Rights Reserved. probechem Copyright
